Evaluation of CSF Levels of Tarceva (OSI-774) in Patients With Stage III Non-Small Cell Lung Cancer and No CNS Involvement Undergoing Treatment With Tarceva
- Determine the cerebrospinal fluid penetration of erlotinib in a subset of patients who
are undergoing treatment with erlotinib for stage III non-small cell lung cancer and
have no CNS metastatic disease.
OUTLINE: This is a pilot, nonrandomized study.
Patients will undergo single lumbar puncture (LP) to remove cerebrospinal fluid for
After completion of study, patients will be monitored for 1 month after LP to assess for any
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
Allocation: Non-Randomized, Primary Purpose: Diagnostic
CSF penetration as measured by CSF fluid via lumbar puncture on day 7 of treatment
Michael A. Vogelbaum, MD, PhD
The Cleveland Clinic
United States: Federal Government
|Cleveland Clinic Taussig Cancer Center||Cleveland, Ohio 44195|